Results 11 to 20 of about 51,509 (201)
Turkish Journal of Orthodontics, 2009 Bisphosphonates are used with the purpose of preventing bone resorption in some metabolic bone diseases. These drugs have been introduced into clinical use about 30 years ago and widely used in nowadays. As Orthodontic some different researches have been
Fırat Öztürk
doaj +2 more sources
Bisphosphonates and osteonecrosis of jaws
Journal of Indian Academy of Oral Medicine and Radiology, 2012 Bisphosphonates are used to treat osteoporosis. Paget disease of bone and other metabolic bone diseases, multiple myeloma, and skeletal events associated with metastatic neoplasms- In 2003, the first reports describing osteonecrosis of the jaw (ONJ) in ...
Geetha Vijay, Vijay Raghavan
doaj +2 more sources
Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis
Patient Preference and Adherence, 2008 Ariane Höer1, Cornelia Seidlitz1, Holger Gothe1, Guido Schiffhorst1, Melvin Olson2, Peyman Hadji3, Bertram Häussler11IGES Institut, Friedrichstrasse 180, D-10117 Berlin, Germany; 2Novartis Pharma AG; 3Department of Gynaecology ...
Ariane Höer +5 more
doaj +1 more source
Türk Osteoporoz Dergisi, 2010 Aim: The aim of this study was to evaluate the effects of bisphosphonates on new fracture development, bone mineral density and biochemical parameters in osteoporotic patients who were treated with these drugs for 5 years. Material and Methods: Thirty
Alev Çevikol +4 more
doaj +1 more source
Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review. [PDF]
, 2013 Osteoarthritis (OA) is the most common form of arthritis worldwide. Pain and reduced function are the main symptoms in this prevalent disease. There are currently no treatments for OA that modify disease progression; therefore analgesic drugs and joint ...
Smith, Toby O +15 more
core +1 more source
Oral Bisphosphonates and Risk of Atrial Fibrillation and Flutter in Women: A Self-Controlled Case-Series Safety Analysis [PDF]
, 2009 Background: A recent trial unexpectedly reported that atrial fibrillation, when defined as serious, occurred more often in participants randomized to an annual infusion of the relatively new parenteral bisphosphonate, zoledronic acid, than among those ...
Aroon Hingorani +14 more
core +1 more source
Research priorities regarding the use of bisphosphonates for osteoporosis: a UK priority setting exercise [PDF]
, 2023 Purpose: Worldwide, many people who would benefit from osteoporosis drugs are not offered or receiving them, resulting in an osteoporosis care gap. Adherence with bisphosphonates is particularly low.
Bastounis, A. +23 more
core +1 more source
Annals of the New York Academy of Sciences, 2006 Abstract: Bisphosphonates belong to a class of compounds similar to pyrophosphate. In these compounds the oxygen atom of the pyrophosphate is replaced by a carbon atom resulting in a P‐C‐P bond. They exert a potent inhibitory effect on osteoclasts and are therefore potent antiresorptive agents. They reduce bone turnover, increase bone mineral density,
Lambrinoudaki, I. +2 more
openaire +3 more sources
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
, 2010 Bisphosphonates are the leading drugs for the treatment of osteoporosis. In randomized controlled trials (RCTs), alendronate, risedronate, and zoledronate have shown to reduce the risk of vertebral, nonvertebral, and hip fractures, whereas RCTs with ...
Graham Russell +8 more
core +2 more sources
Bisphosphonate nephrotoxicity [PDF]
Kidney International, 2008 Bisphosphonates are valuable agents for the treatment of post-menopausal osteoporosis (PMO), hypercalcemia of malignancy, and osteolytic bone metastases. Oral bisphosphonates are used mainly to treat PMO and are not associated with significant nephrotoxicity.
Perazella, Mark A., Markowitz, Glen S.
openaire +2 more sources